PerkinElmer, Inc. — Form 10-Q Summary
Issuer identification: The supplied filing identifies the registrant as PerkinElmer, Inc. (NYSE: PKI), not Revvity, Inc. Confirm that this is the intended filing before relying on the summary.
Business context and reporting period
The unaudited report covers the three months ended April 3, 2022, compared with the three months ended April 4, 2021. PerkinElmer reports Discovery & Analytical Solutions and Diagnostics segments, serving life sciences, applied markets and diagnostics.
Key financial metrics
| Metric | Q1 2022 | Prior-year quarter |
|---|---|---|
| Revenue | $1,259.4 million | $1,307.7 million |
| Gross margin | 53.9% | 60.0% |
| Operating income | $254.8 million | $467.8 million |
| Income from continuing operations | $177.0 million | $379.3 million |
| Diluted EPS | $1.40 | $3.37 |
| Operating cash flow | $283.2 million | $473.5 million |
Revenue declined 4%; operating income fell 46%, and income from continuing operations fell 53%. Cash and cash equivalents were $669.8 million at quarter-end, versus $618.3 million at January 2, 2022. Total debt carrying value was approximately $4.9 billion, including $3.7 million current debt. The company reported $1.5 billion of available capacity under its revolving credit facility.
- Segments: Discovery & Analytical Solutions revenue rose 33% to $602.4 million, while operating income declined to $14.5 million from $42.9 million. Diagnostics revenue fell 23% to $657.1 million, and operating income declined to $258.0 million from $441.5 million.
- Cash uses: Investing activities used $56.3 million, including $29.4 million of capital expenditures. Financing activities used $164.9 million, including $100 million of term-loan repayment, $55.6 million of share repurchases and $8.8 million of dividends paid.
- Shareholder returns: The quarterly dividend was $0.07 per share. The repurchase program had $144.0 million remaining as of April 3, 2022.
Material changes and management commentary
Diagnostics revenue was pressured by a $239.7 million decline in COVID-19 product revenue, partly offset by $43.7 million growth in the core portfolio. Discovery & Analytical Solutions benefited from 2021 acquisitions and organic growth in pharmaceutical, biotechnology, industrial and food markets; unfavorable foreign exchange partly offset growth.
Gross margin contracted 611 basis points. Management attributed the decline mainly to higher acquired-intangible amortization and lower COVID-19 revenue, partly offset by product mix and service productivity. Operating margin declined 1,554 basis points, primarily reflecting higher acquisition-related amortization and investment in product development and growth initiatives. Higher SG&A, R&D and interest expense also weighed on results.
Operating cash flow decreased $190.3 million year over year, reflecting lower profitability and cash used in working capital, compared with cash provided by working capital in the prior-year quarter. The company repaid an additional $230 million of term-loan principal after quarter-end.
Outlook, risks and unusual items
- California laboratory contract: CDPH notified the company that it intends to end the Valencia Branch Laboratory contract effective May 15, 2022, citing reduced COVID-19 testing demand. A $126.2 million unamortized contract liability was reported at March 31; the company expected to recognize $117.8 million as revenue in Q2 2022 through the contract’s remaining period. This recognition is not recurring operating demand and the contract termination may affect subsequent revenue.
- Outlook: The provided filing text does not state a clear numerical revenue or earnings forecast. Management said it expects internal cash generation to cover operating expenses, capital expenditures, smaller acquisitions, debt interest and dividends, while larger acquisitions and debt maturities may require external funding. It expects COVID-19-related Diagnostics demand to continue declining during the rest of fiscal 2022.
- Key risks: COVID-19 demand normalization and laboratory closures; acquisition integration and substantial goodwill and intangible assets; foreign exchange exposure; supply-chain and geopolitical disruption, including the Ukraine conflict; inflation and market volatility; debt service, variable interest rates and financing access; regulatory, litigation and environmental contingencies.
- Other items: Q1 included $13.4 million of restructuring and other costs and $12.1 million of expense from changes in fair value of financial securities. Environmental remediation accruals were $12.0 million. Management stated that pending claims and proceedings were not expected to have a material adverse effect, while noting outcomes remain uncertain. Disclosure controls were assessed as effective.
Most important facts for investors to verify
- Confirm the issuer and ticker: this source is a PerkinElmer (PKI) filing, despite the request naming Revvity, Inc.
- Review the timing, amount and nonrecurring nature of the expected $117.8 million Q2 revenue recognition tied to the CDPH contract.
- Assess how continued COVID-19 demand declines and acquired-business amortization may affect Diagnostics revenue, consolidated margins and earnings.
- Check subsequent debt repayment, liquidity, borrowing costs and cash flow against the approximately $4.9 billion debt balance and $1.5 billion revolver availability.
- Evaluate acquisition integration, impairment sensitivity and the assumptions supporting goodwill and intangible-asset carrying values.